Comparative Pharmacology
Head-to-head clinical analysis: BRETHINE versus ISOETHARINE MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRETHINE versus ISOETHARINE MESYLATE.
BRETHINE vs ISOETHARINE MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing intracellular cAMP, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Selective beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing cAMP in bronchial smooth muscle, leading to bronchodilation.
5 mg orally three times daily; may increase to 10 mg if needed; maximum 20 mg daily. Subcutaneous: 0.25 mg, may repeat once in 15-30 minutes (not to exceed 0.5 mg in 4 hours).
Inhalation: 1-2 inhalations (0.34 mg per actuation) via metered-dose inhaler every 4-6 hours as needed; or 0.25-0.5 mL of 1% solution diluted in 2-3 mL of normal saline via nebulizer every 4-6 hours.
None Documented
None Documented
3-8 hours (terminal); shorter in children and smokers; prolonged in hepatic impairment
Terminal elimination half-life is approximately 2.5–5 hours in adults after inhalation; may be prolonged in patients with hepatic or renal impairment.
Renal: 50-60% as unchanged drug and metabolites; biliary/fecal: 20-30%
Primarily renal excretion of unchanged drug and metabolites (sulfate and glucuronide conjugates); approximately 40-50% excreted renally as unchanged drug within 24 hours, with the remainder as metabolites. Biliary/fecal excretion is minimal (<5%).
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist